Journal
PAIN MANAGEMENT
Volume 11, Issue 3, Pages 249-258Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pmt-2020-0082
Keywords
iv. push; meloxicam iv; nanocrystal; nonsteroidal anti-inflammatory drug; once-daily administration; postoperative pain
Categories
Funding
- Baudax Bio Inc.
- Recro/Baudax
Ask authors/readers for more resources
Meloxicam for intravenous use is an effective pain reliever following surgery, with reduced opioid consumption and a similar adverse event profile to placebo. It does not adversely affect platelet function or wound healing parameters.
Meloxicam for intravenous use (meloxicam iv.) is a nanocrystal formulation with improved dissolution properties and shortened time to peak plasma concentrations versus oral meloxicam. In Phase III and IIIb trials, 30 mg once daily relieved pain following pre- or postoperative administration in orthopedic, abdominal and colorectal surgeries. Meloxicam iv. was associated with reduced opioid consumption, the clinical benefit of which remains unclear. The drug may be administered alone or in combination with other non-nonsteroidal anti-inflammatory drugs. In Phase III trials, it demonstrated adverse event profile similar to placebo, with nausea, constipation, vomiting and headache occurring most frequently. Meloxicam iv. does not appear to adversely affect platelet function or wound-healing parameters. No new safety signals were detected in the Phase IIIb studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available